Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study
about
AcromegalyClinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluationAcromegaly pathogenesis and treatmentCombined treatment of somatostatin analogues with pegvisomant in acromegalyNeed for improved monitoring in patients with acromegalyA dominant-negative FGF1 mutant (the R50E mutant) suppresses tumorigenesis and angiogenesisMolecular mechanistic associations of human diseasesPegvisomant in acromegaly: an update.Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guidelineOptic neuropathy in McCune-Albright syndrome: effects of early diagnosis and treatment of growth hormone excessLong-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDYTargeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and ExpectationsGamma knife radiosurgery for acromegaly.Clinical and radiological evidence of the recurrence of reversible pegvisomant-related lipohypertrophy at the new site of injection in two women with acromegaly: a case series.Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study.Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes.Pegvisomant in acromegaly: why, when, how.Growth hormone excess and the development of growth hormone receptor antagonists.Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults.The management of the patient with acromegaly and headache: a still open clinical challenge.Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial.Self-limited acute hepatotoxicity caused by pegvisomant.The role of primary pharmacological therapy in acromegaly.Pegvisomant: current and potential novel therapeutic applications.Octreotide long-acting repeatable for acromegaly.Estrogen and selective estrogen receptor modulators (SERMs) for the treatment of acromegaly: a meta-analysis of published observational studies.Pegvisomant-Induced Cholestatic Hepatitis in an Acromegalic Patient with UGT1A1 (⁎) 28 Mutation.Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly.Current and future medical treatments for patients with acromegaly.The role of combination medical therapy in the treatment of acromegaly.Crosstalk between insulin-like growth factor (IGF) receptor and integrins through direct integrin binding to IGF1.Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities.Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes.Effect of rosiglitazone on serum IGF-I concentrations in uncontrolled acromegalic patients under conventional medical therapy: results from a pilot phase 2 study.Targeting the insulin-like growth factor pathway in rhabdomyosarcomas: rationale and future perspectives.Long-term treatment with pegvisomant for acromegaly: a 10-year experience.Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY.Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience.Multi-modal management of acromegaly: a value perspective.Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3.
P2860
Q21202912-5475E00A-7540-4B34-A86D-E12B7D41C7F7Q21254711-4114588F-0E16-4200-ADCC-D1C6A31F7134Q24647360-BA65F9AD-47EF-4BC7-B73B-F341DA7628B1Q26776366-E753D588-3FCA-4638-B364-A33E014535CFQ26783670-6674F889-ADE4-4001-A626-0562A7465D88Q28118161-83EE3E25-E2F4-484A-84A0-A1C32B05CCA4Q30496754-A7C7E785-3731-465B-913F-A6D0425FBCF5Q33725999-35448B26-2310-42DC-B021-855524F76C42Q34277844-1610CF14-5F9E-4C2C-9C39-934CAAB5BF01Q34307900-66E3D5E9-D32F-43CB-8EBD-5C200EEC4FF7Q34446297-304FCB67-795C-48F5-AA46-287ECF34690AQ35013284-99EEFD51-488E-45BB-BD50-66FAFBFF1EEAQ35810502-DD7B4018-8AAB-4223-9DB0-9474A2394F64Q36099208-B098A863-16A7-4339-8E31-222E59EA0658Q36119677-D0637F9A-A5E8-4DA9-9340-B0C0ECF584A3Q36964536-CC15C725-E34E-41BE-9763-2B5BCEA5520DQ36965612-08DB5E51-40E4-4557-AB3F-82AA7D037D00Q37212629-8BA424B6-6A47-4399-8C33-160B6E993714Q37321948-DE429EA5-CEC1-4B28-99CC-D8F7839D621AQ37353632-F11D2654-18DB-4A2F-95DC-E3EC9B0DF351Q37394470-7D8A4BE1-E85A-4EA3-BBDF-FBD942A64BB4Q37407902-4FF8AE2A-BBCD-4977-8934-DE732DD25FDDQ37531005-C7A48264-8011-4E7A-9A41-E71AFCF2B7A4Q37633543-1CB6D655-DCDE-4BB4-B4F1-93EB6FE9F1A1Q37990556-CE3324CC-249D-4EFA-9FC8-E2E98731EE36Q38127391-537F710B-C8E9-49B1-A4C0-BA6B1C9B4AC9Q38591741-C7CE6A8D-F0A4-4CA6-B0E3-7AD8A30955CFQ38683309-4D232F03-1855-4AE0-BA7B-58A6DF68DE5CQ38847622-A156A624-5623-4769-B038-779EB3F97A72Q38927318-DE12A2FC-8BCC-421F-9C7B-B1B03C6BD7AEQ39132510-D439F29F-34C2-4401-B912-E6C0147BE3CFQ39146196-2FBF3B19-FA4D-40E3-B85F-5EDD981AFE16Q39306199-8357EDFB-3E6F-45D3-8969-B2E5DDEDDAEAQ39673688-6FAD1A9F-7774-49D3-8F80-5CA1B2FA2C6AQ39767891-5FF0C515-66B7-4226-B014-7A1BC6069A4DQ40216531-6E4EB6D5-0576-4F3D-803E-35305EF606D7Q40339066-CD811133-2E94-4A83-B48A-78DE471A06F6Q41009206-59D384F4-FB64-4387-A357-8F9229AC62BBQ41627761-06AC3E69-81F1-4A30-9B9C-46F21D5E9B6BQ41673741-58DB7FE7-ADC9-457B-8704-63E40AF0D5AB
P2860
Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Treatment of acromegaly with t ...... egvisomant Observational Study
@ast
Treatment of acromegaly with t ...... egvisomant Observational Study
@en
Treatment of acromegaly with t ...... egvisomant Observational Study
@nl
type
label
Treatment of acromegaly with t ...... egvisomant Observational Study
@ast
Treatment of acromegaly with t ...... egvisomant Observational Study
@en
Treatment of acromegaly with t ...... egvisomant Observational Study
@nl
prefLabel
Treatment of acromegaly with t ...... egvisomant Observational Study
@ast
Treatment of acromegaly with t ...... egvisomant Observational Study
@en
Treatment of acromegaly with t ...... egvisomant Observational Study
@nl
P2093
P3181
P356
P1476
Treatment of acromegaly with t ...... egvisomant Observational Study
@en
P2093
C J Strasburger
I Schreiber
K Forssmann
M Buchfelder
P3181
P356
10.1530/EJE.1.02312
P407
P577
2007-01-01T00:00:00Z